Epidermal growth factor receptor expression as a prognostic indicator in breast cancer - PubMed (original) (raw)
Epidermal growth factor receptor expression as a prognostic indicator in breast cancer
M Toi et al. Eur J Cancer. 1991.
Abstract
The significance of epidermal growth factor receptor (EGFR) status as a prognostic indicator was investigated by a competitive binding assay in 135 primary breast cancer patients. 55 patients (41%) were EGFR positive and EGFR status was negatively correlated with oestrogen receptor (ER) status (P less than 0.01). 5-year postoperative follow-up showed that relapse-free survival for EGFR positive patients was significantly worse than that for EGFR negative patients (P less than 0.05). There was no difference between the two groups in tumour size, axillary node involvement, age and menopausal status. Analysis by axillary node status demonstrated the poor prognosis of the EGFR positive group in node positive patients. As yet, no difference in prognosis has been seen in node negative patients. A higher frequency of haematopoietic relapse was observed in EGFR positive patients. Simultaneous or sequential EGFR measurements in primary tumour and metastatic sites of 34 patients showed that expression of EGFR was more enhanced in metastatic sites.
Similar articles
- Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status.
Sacks NP, Smith K, Norman AP, Greenall M, LeJeune S, Harris AL. Sacks NP, et al. Eur J Cancer. 1993;29A(3):426-8. doi: 10.1016/0959-8049(93)90401-z. Eur J Cancer. 1993. PMID: 8398346 - Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Sainsbury JR, et al. Lancet. 1987 Jun 20;1(8547):1398-402. doi: 10.1016/s0140-6736(87)90593-9. Lancet. 1987. PMID: 2884496 - Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.
Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Tsutsui S, et al. Breast Cancer Res Treat. 2002 Jan;71(1):67-75. doi: 10.1023/a:1013397232011. Breast Cancer Res Treat. 2002. PMID: 11859875 - EGF receptor expression, regulation, and function in breast cancer.
Chrysogelos SA, Dickson RB. Chrysogelos SA, et al. Breast Cancer Res Treat. 1994 Jan;29(1):29-40. doi: 10.1007/BF00666179. Breast Cancer Res Treat. 1994. PMID: 8018962 Review. - Critical review of growth factors as clinical tools in primary and metastatic breast cancer.
Klijn JG, Berns PM, van Putten WL, Bontenbal M, Alexieva-Figusch J, Foekens JA. Klijn JG, et al. Recent Results Cancer Res. 1993;127:77-88. doi: 10.1007/978-3-642-84745-5_11. Recent Results Cancer Res. 1993. PMID: 8099227 Review. No abstract available.
Cited by
- The silent estrogen receptor--can we make it speak?
Billam M, Witt AE, Davidson NE. Billam M, et al. Cancer Biol Ther. 2009 Mar 15;8(6):485-96. doi: 10.4161/cbt.8.6.7582. Epub 2009 Mar 15. Cancer Biol Ther. 2009. PMID: 19411863 Free PMC article. Review. - Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.
Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllönen L, von Smitten K. Railo M, et al. Br J Cancer. 1993 Sep;68(3):579-83. doi: 10.1038/bjc.1993.389. Br J Cancer. 1993. PMID: 8394732 Free PMC article. - FAM83B mediates EGFR- and RAS-driven oncogenic transformation.
Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, Brown HA, Stark GR, Jackson MW. Cipriano R, et al. J Clin Invest. 2012 Sep;122(9):3197-210. doi: 10.1172/JCI60517. Epub 2012 Aug 13. J Clin Invest. 2012. PMID: 22886302 Free PMC article. - The epidermal growth factor receptor in breast cancer.
Fox SB, Harris AL. Fox SB, et al. J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):131-41. doi: 10.1023/a:1026399613946. J Mammary Gland Biol Neoplasia. 1997. PMID: 10882299 Review. - Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.
Toi M, Tominaga T, Osaki A, Toge T. Toi M, et al. Breast Cancer Res Treat. 1994 Jan;29(1):51-8. doi: 10.1007/BF00666181. Breast Cancer Res Treat. 1994. PMID: 7912567 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous